Status:

COMPLETED

Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis

Lead Sponsor:

Zhuan Zhang

Conditions:

Peripheral Facial Palsy

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

Peripheral facial palsy is caused by damage to the facial nerve at any site of the peripheral branches after the facial nucleus.Stellate ganglion block is performed to treat peripheral facial palsy be...

Eligibility Criteria

Inclusion

  • Diagnosed by clinical and neurological assessment as one-sided simple facial
  • Age 18 to 75 years
  • HBGS above Ⅳ
  • the course of IFP not over 7 days.

Exclusion

  • Coagulation dysfunction
  • plate plate plate shape, quantity or abnormal function
  • mental system diseases
  • Gillan-Bahrain syndrome
  • cancer, mumps, shingles infection, jaw facial pus lymph nodeitis, encephalitis, -cerebral hemorrhage and other diseases
  • local infection or systemic infectious disease at the puncture site
  • can not accept to nerve block

Key Trial Info

Start Date :

March 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 30 2022

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT04800666

Start Date

March 1 2021

End Date

March 30 2022

Last Update

November 22 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

the Affiliated Hospital of Yangzhou University

Yangzhou, Jiangsu, China